윈드트리 테라퓨틱스(WINT)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.00 (+0.00%), 시가총액 $0.00B, PER 0.00, 52주 범위 $0.01 ~ $1.19.
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant for the treatment of respiratory disease, disorder, or condition in humans; Rostafuroxin, which is in Phase 2b clinical trials for the treatment of genetical
윈드트리 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
윈드트리 테라퓨틱스의 현재 주가는 $0.00 (+0.00%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
윈드트리 테라퓨틱스의 시가총액은 약 $0.00B입니다. PER은 0.00입니다.
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is